William III - 2Seventy Bio Chief Officer

2Seventy Bio Management Efficiency

The company has return on total asset (ROA) of (0.1902) % which means that it has lost $0.1902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5189) %, meaning that it created substantial loss on money invested by shareholders. 2Seventy Bio's management efficiency ratios could be used to measure how well 2Seventy Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.45 in 2024. At this time, 2Seventy Bio's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 574.1 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 2.3 M in 2024.

Similar Executives

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people. 2Seventy Bio (TSVT) is traded on NASDAQ Exchange in USA. It is located in 60 Binney Street, Cambridge, MA, United States, 02142 and employs 274 people. 2Seventy Bio is listed under Biotechnology category by Fama And French industry classification.

Management Performance

2Seventy Bio Leadership Team

2Seventy Stock Performance Indicators

Additional Tools for 2Seventy Stock Analysis